Samsung Biologics, a global contract development and manufacturing organization (CDMO), has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner—making it the first Korean CDMO to participate in the PSCI, a group of pharmaceutical and healthcare companies that share a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain.
 
Samsung Biologics will commit to PSCI principles that address five areas of responsible business practice:
 

• Ethics
• Labor
• Health & safety
• Environment
• Management systems

 
Samsung Biologics expects the partnership to help further advance the company’s dedication to sustainable growth and strengthen its Environmental, Social, and Governance (ESG) management. As part of its efforts to decarbonize and build more resilient supply chains, Samsung Biologics has been engaging suppliers as champion of the Supply Chains Working Group within the Sustainable Market Initiative’s Health Systems Task Force.
 
“We are pleased to join the PSCI and hope to actively support collective actions to improve supply chain management,” said John Rim, CEO and President of Samsung Biologics. “As part of our commitment to deliver safe, high-quality biomedicines, we will incorporate PSCI principles into our business practices and promote responsible conduct among our suppliers to drive sustainable change across the supply chain, contributing to a healthier future.”

Related News

Samsung Biologics recently signed a $1.06 billion manufacturing agreement with an undisclosed U.S.-based pharmaceutical company following a letter of intent (LOI) signed in June of last year.